Management & Board of Directors
President & Chief Executive Officer
Mr. Howlett founded Skinvisible, Inc. in 1998. With over 30 years of entrepreneurial, business management and market initialization experience, he drives and directs the Company's development and technology vision. He is adept at guiding emerging and publicly traded start-up companies through the stages of capital formation, strategic planning and business growth; specializing in venture capital financing. Mr. Howlett's diversified background includes senior management, marketing, and sales positions with both established and start-up companies.
James A. Roszell
Dr. James Roszell is a doctoral chemist with over 35 years' experience in product formulation, experimental design, analysis, and method validation. Since joining Skinvisible in 1998, he has been responsible for research and development of the Company's patented technology, related polymer delivery vehicles, product formulations and compositions. Dr. Roszell is a joint contributor to Skinvisible's Patent Number 6.756.059 and responsible for its four pending patents. Prior to joining Skinvisible, he worked as chemist for Supertech Products, Inc. in Florida where his responsibilities included ensuring compliance with OSHA, EPA and other standards and regulations, maintenance of quality control, research and development for new products. Dr. Roszell's background includes work in chemical, pharmaceutical, environmental and clinical laboratory arenas. His invaluable chemical and scientific expertise are key factors in Skinvisible's innovative technological achievements.
Vice President, Business Development
Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last six years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few. Ms. McMorran, who holds a Bachelor of Commerce (Honours) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.
Board of Directors:
President & Chief Executive Officer
Mr. McCartney is Chairman of the Board and Managing Director of Taylor Butterfield & Worth Asset Management Corporation, a privately held equities firm. He has held senior executive and director positions in five North American Exchange listed companies and is presently President of a privately held investment firm, Aspenwood Holdings Corporation. He has over 20 years of capital markets experience and has been instrumental in supporting the financial requirements for several small to medium sized businesses over a broad market sector. Mr. McCartney is responsible for the corporate development and marketing initiatives of TBW services. and is the past President and Chief Executive Officer of Biolabs Inc., a biotechnology company, he founded in 1997.
Latest Press Releases:
November 27, 2017
Skinvisible Announces Proposed Merger with Quoin Pharmaceuticals - New company expected to have an exciting product portfolio addressing major unmet medical needs
November 16, 2017
New Skinvisible, Inc. (SKVI) Subsidiary Signs Exclusive License Agreement to Distribute Its Topical Cannabis Products in the USA
September 28, 2017
Canopy Growth and Skinvisible Sign Definitive Agreement to Bring New Products to Market
July 7, 2017
Skinvisible Improves the Delivery of Cannabis with Patented Invisicare Technology - Topical and Transdermal Product Licensing Opportunities Available in the US and Globally
CLICK HERE TO READ ALL NEWS RELEASES